Hepatology Research最新文献

{"title":"Changes in alanine aminotransferase and body composition and metabolic factors among individuals receiving medical health checkups","authors":"Saori Onishi,&nbsp;Akira Fukuda,&nbsp;Masahiro Matsui,&nbsp;Kosuke Ushiro,&nbsp;Tomohiro Nishikawa,&nbsp;Akira Asai,&nbsp;Soo Ki Kim,&nbsp;Hiroki Nishikawa","doi":"10.1111/hepr.14087","DOIUrl":"10.1111/hepr.14087","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To examine the relationship between changes in alanine aminotransferase (ALT) and those in body composition and metabolic factors in participants receiving medical health checkups (4350 men [mean age 52.5 years] and 5398 women [mean age 50.5 years])</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We divided the participants into four types based on their ALT value at baseline and 1 year: A, ALT ≤30 (baseline) and ≤30 (1 year); B, ALT ≥31 (baseline) and ≤30 (1 year); C, ALT ≤30 (baseline) and ≥31 (1 year); and D, ALT ≥31 (baseline) and ≥31 (1 year). The change in each body composition-related parameter (waist circumference, fat mass, fat-free mass, fat mass to fat-free mass ratio, etc.) after 1-year was defined as Δ.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean changes in waist circumference (cm) in the four types (A, B, C, and D) were −0.33, −1.54, 0.66, and −0.29 (overall <i>p</i> &lt; 0.0001) in men, and −0.19, −0.90, 0.30, and 0.090 (overall <i>p</i> &lt; 0.0001) in women. The mean changes in fat mass (kg) in the four types were −0.027, −0.86, 0.62, and 0.092 (overall <i>p</i> &lt; 0.0001) in men, and 0.0067, −0.48, 0.39, and 0.063 (overall <i>p</i> &lt; 0.0001) in women. The mean changes in fat-free mass (kg) in the four types were −0.028, −0.55, 0.42, and −0.034 (overall <i>p</i> &lt; 0.0001) in men, and −0.0091, −0.34, 0.12, and −0.045 (overall <i>p</i> = 0.0012) in women. The mean changes in fat mass to fat-free mass ratio in the four types were −0.00042, −0.0120, 0.00837, and 0.00171 (overall <i>p</i> &lt; 0.0001) in men, and −0.00013, −0.00817, 0.00730, and 0.00628 (overall <i>p</i> &lt; 0.0001) in women.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A decrease in ALT to ≤30 IU/L may be associated with improved body composition balance, but caution should be exercised for the decrease in muscle mass.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"54 12","pages":"1193-1204"},"PeriodicalIF":3.9,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma","authors":"Teh-Ia Huo,&nbsp;Shu-Yein Ho","doi":"10.1111/hepr.14082","DOIUrl":"10.1111/hepr.14082","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"54 12","pages":"1235"},"PeriodicalIF":3.9,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141529779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”","authors":"Wei Huang,&nbsp;Yan Zheng","doi":"10.1111/hepr.14080","DOIUrl":"10.1111/hepr.14080","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"54 12","pages":"1234"},"PeriodicalIF":3.9,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141527065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of risk alleles of PNPLA3, TM6SF2, and HSD17B13 of donors can predict recurrence of steatotic liver disease after liver transplantation","authors":"Kenta Makino,&nbsp;Takamichi Ishii,&nbsp;Satoshi Ogiso,&nbsp;Akiyoshi Nakakura,&nbsp;Takahiro Nishio,&nbsp;Ken Fukumitsu,&nbsp;Elena Yukie Uebayashi,&nbsp;Fumiaki Munekage,&nbsp;Hiroshi Horie,&nbsp;Kentaro Iwaki,&nbsp;Takashi Ito,&nbsp;Etsuro Hatano","doi":"10.1111/hepr.14086","DOIUrl":"10.1111/hepr.14086","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to identify the genetic risk factors from donors or recipients that contribute to postliver transplantation (LT) steatotic liver disease (SLD), focusing on the genetic risk score (GRS) based on single nucleotide polymorphisms (SNPs) in SLD patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study included 55 Japanese SLD recipients and their respective donors. Genotyping of <i>PNPLA3</i>, <i>TM6SF2</i>, and <i>HSD17B13</i> was undertaken, and the combined GRS was calculated. The relationship between the GRS and the incidence of posttransplant SLD was also evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The SLD recipients had a high prevalence of post-LT graft steatosis/steatohepatitis (76.4% and 58.2%, respectively). Although the recipients had a high frequency of risk alleles, there was no relationship between the number of risk alleles for each SNP and the incidence of posttransplant SLD. In contrast, an increased number of risk alleles for any SNP in the donor was correlated with high incidence rates of both post-LT steatosis and steatohepatitis. A multivariable analysis showed that a high donor GRS was an independent risk factor for graft steatosis (odds ratio 8.77; 95% CI, 1.94–52.94; <i>p</i> = 0.009). Similarly, a high donor GRS was an independent risk factor (odds ratio 6.76; 95% CI, 1.84–30.78; <i>p</i> = 0.007) for post-LT graft steatohepatitis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Donor risk alleles of <i>PNPLA3</i>, <i>TM6SF2</i>, and <i>HSD17B13</i>, rather than recipient risk alleles, have been implicated in the development of posttransplant SLD. The combination of these donor risk alleles into a GRS could predict the development of posttransplant SLD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"54 12","pages":"1148-1157"},"PeriodicalIF":3.9,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141527064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic guide for immune checkpoint inhibitor-induced liver injury","authors":"Takanori Ito,&nbsp;Yasuto Takeuchi,&nbsp;Kazuyuki Mizuno,&nbsp;Michitaka Imai,&nbsp;Yoko Yoshimaru,&nbsp;Kazumichi Abe,&nbsp;Masanori Abe,&nbsp;Takanori Matsuura,&nbsp;Masataka Yokode,&nbsp;Masahiro Shiokawa,&nbsp;Yuzo Kodama,&nbsp;Mina Komuta,&nbsp;Kenichi Harada,&nbsp;Atsushi Tanaka","doi":"10.1111/hepr.14078","DOIUrl":"10.1111/hepr.14078","url":null,"abstract":"<p>With the widespread use of immune checkpoint inhibitors (ICIs), liver injury (ICI-induced liver injury) as an immune-related adverse event has become a major concern in clinical practice. Because severe cases of liver injury require administration of corticosteroids, a comprehensive evaluation is crucial, including clinical course, blood and imaging tests, and if necessary, pathological examination through liver biopsy. As with liver injury induced by other drugs, classification of injury type by <i>R</i>-value is useful in deciding treatment strategies for ICI-induced liver injury. Histologically, the most representative feature is an acute hepatitis-like hepatocellular injury, characterized by diffuse lobular inflammation accompanied by CD8-positive T lymphocytes. Another condition that can cause liver injury during ICI treatment is cholangitis accompanied by non-obstructive bile duct dilatation and bile duct wall thickening. Many cases of ICI-induced cholangitis are classified as non-hepatocellular injury type, and they have been reported to respond poorly to corticosteroids. It is essential that gastroenterologists/hepatologists and doctors in various departments work in cooperation to develop a system that achieves early diagnosis and appropriate treatment of ICI-induced liver injury.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"54 8","pages":"719-726"},"PeriodicalIF":3.9,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.14078","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication","authors":"Takahiko Sakaue,&nbsp;Hiroya Terabe,&nbsp;Hidetoshi Takedatsu,&nbsp;Takumi Kawaguchi","doi":"10.1111/hepr.14081","DOIUrl":"10.1111/hepr.14081","url":null,"abstract":"<p>Extrahepatic malignancies are the leading cause of death in patients with nonalcoholic fatty liver disease (NAFLD). Of these cancers, pancreatic cancer is one of the most lethal; however, the link between NAFLD and pancreatic cancer remains unclear. Recently, various research results have been reported on the association between NAFLD and pancreatic cancer, and the results of compiling this information revealed the following. First, the prevalence of pancreatic cancer in patients with NAFLD is at 0.26%. Second, the currently evident pathogenesis includes intrapancreatic risk factors, such as: (1) non-alcoholic fatty pancreas disease, and (2) intraductal papillary mucinous neoplasm; and extrapancreatic risk factors, such as: (1) insulin resistance and adipocytokines, (2) proinflammatory cytokines, and (3) dysbiosis. Finally, metformin and sodium–glucose cotransporter 2 inhibitors may reduce the risk of pancreatic cancer in diabetes patients with NAFLD. In this review, we summarize the recent evidence on the epidemiology and mechanisms for NAFLD-related pancreatic cancer. We further discuss the impact of anti-diabetic medication on pancreatic cancer.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"54 8","pages":"729-735"},"PeriodicalIF":3.9,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan","authors":"Yasue Takeuchi,&nbsp;Akinori Nozawa,&nbsp;Atsushi Yukimoto,&nbsp;Masayuki Kitsuka,&nbsp;Ryosuke Tateishi,&nbsp;Kazuhiko Koike,&nbsp;Kazuyuki Okano,&nbsp;Tatsuya Kanto","doi":"10.1111/hepr.14085","DOIUrl":"10.1111/hepr.14085","url":null,"abstract":"<p>Chronic hepatitis B and C are among the most significant infectious diseases worldwide, and are major risk factors for liver cirrhosis and liver cancer. In Japan, comprehensive hepatitis measures are implemented for the testing and treatment of viral hepatitis, thus enabling the early diagnosis of liver cancer. Nevertheless, patients with decompensated cirrhosis and liver cancer often have unfavorable prognoses and require repetitive long-term treatment. In fiscal year 2018, an integrated policy of medical expense subsidies and research was established in Japan that aimed to alleviate patients' financial burden and launch the clinical registry of advanced liver disease. Over time, updates to the eligibility for the subsidy increased access to patients and has led to an increased number of beneficiaries. Additionally, the accumulation of clinical data in the registry has revealed the treatment choices for these diseases. However, the disparities in efforts across prefectures have also become evident. Raising public awareness of the policy and tightening the multisector healthcare network are keys to success in supporting qualifying patients with advanced liver disease.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"54 8","pages":"745-752"},"PeriodicalIF":3.9,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab","authors":"Kei Endo,&nbsp;Keisuke Kakisaka,&nbsp;Tamami Abe,&nbsp;Kenji Yusa,&nbsp;Ippeki Nakaya,&nbsp;Takuya Watanabe,&nbsp;Hiroaki Abe,&nbsp;Akiko Suzuki,&nbsp;Yuichi Yoshida,&nbsp;Takayoshi Oikawa,&nbsp;Akio Miyasaka,&nbsp;Hidekatsu Kuroda,&nbsp;Takayuki Matsumoto","doi":"10.1111/hepr.14084","DOIUrl":"10.1111/hepr.14084","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>An accurate assessment of the general condition of patients with hepatocellular carcinoma (HCC) is essential. We evaluated the impact of grip strength (GS) and Eastern Cooperative Oncology Group Performance Status (ECOG-PS) on the clinical outcomes of patients with unresectable HCC (u-HCC) treated with atezolizumab plus bevacizumab.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This observational cohort study analyzed 89 patients with u-HCC treated with atezolizumab plus bevacizumab between October, 2020 and October, 2023. A Cox proportional hazards model and Kaplan–Meier curve were used to identify the prognostic factors associated with survival outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 33 patients who had low GS and 16 had an ECOG-PS ≥1. The frequency of patients with low GS increased as the ECOG-PS score increased. The overall survival of the normal GS group was significantly higher than that of the low GS group (<i>p</i> &lt; 0.01). There was no significant difference in progression-free survival between the normal GS group and low-GS group (<i>p</i> = 0.28). Among the patients in the ECOG-PS 0 groups, the overall survival in the normal GS group was significantly higher than that in the low GS group (<i>p</i> &lt; 0.01). A multivariate analysis revealed that modified albumin-bilirubin 2b (HR 2.24; 95% confidence interval [CI] 1.06–4.73), α-fetoprotein ≥100 ng/mL (HR 2.35; 95% CI 1.20–4.58), and low GS (HR 2.87; 95% CI 1.31–6.27) were independently associated with a poor overall survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The present study demonstrated that GS is a sensitive marker for detecting a subclinical decline in the general condition and is therefore a potential predictor of the outcome of u-HCC patients treated with atezolizumab plus bevacizumab.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"54 12","pages":"1158-1173"},"PeriodicalIF":3.9,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in hepatitis E virus research and the Japanese clinical practice guidelines for hepatitis E virus infection","authors":"Tatsuo Kanda,&nbsp;Tian-Cheng Li,&nbsp;Masaharu Takahashi,&nbsp;Shigeo Nagashima,&nbsp;Putu Prathiwi Primadharsini,&nbsp;Satoshi Kunita,&nbsp;Reina Sasaki-Tanaka,&nbsp;Jun Inoue,&nbsp;Atsunori Tsuchiya,&nbsp;Shingo Nakamoto,&nbsp;Ryuzo Abe,&nbsp;Keiichi Fujiwara,&nbsp;Osamu Yokosuka,&nbsp;Ryosuke Suzuki,&nbsp;Koji Ishii,&nbsp;Hiroshi Yotsuyanagi,&nbsp;Hiroaki Okamoto,&nbsp;The AMED HAV and HEV Study Group","doi":"10.1111/hepr.14062","DOIUrl":"10.1111/hepr.14062","url":null,"abstract":"<p>Acute hepatitis E was considered rare until reports emerged affirming the existence of hepatitis E virus (HEV) genotypes 3 and 4 infections in Japan in the early 2000s. Extensive studies by Japanese researchers have highlighted the pivotal role of pigs and wild animals, such as wild boars and deer, as reservoirs for HEV, linking them to zoonotic infections in Japan. Currently, when hepatitis occurs subsequent to the consumption of undercooked or grilled pork, wild boar meat, or offal (including pig liver and intestines), HEV infection should be considered. Following the approval of anti-HEV immunoglobulin A antibody as a diagnostic tool for hepatitis E by Japan's Health Insurance System in 2011, the annual number of diagnosed cases of HEV infection has surged. Notably, the occurrence of post-transfusion hepatitis E promoted nationwide screening of blood products for HEV using nucleic acid amplification tests since 2020. Furthermore, chronic hepatitis E has been observed in immunosuppressed individuals. Considering the significance of hepatitis E, heightened preventive measures are essential. The Japan Agency for Medical Research and Development Hepatitis A and E viruses (HAV and HEV) Study Group, which includes special virologists and hepatologists, held a virtual meeting on February 17, 2024. Discussions encompassed pathogenesis, transmission routes, diagnosis, complications, severity factors, and ongoing and prospective vaccination or treatments for hepatitis E. Rigorous assessment of referenced studies culminated in the formulation of recommendations, which are detailed within this review. This comprehensive review presents recent advancements in HEV research and Japanese clinical practice guidelines for HEV infection.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"54 8","pages":"1-30"},"PeriodicalIF":3.9,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low liver reserve is a risk factor for acute pancreatitis in patients with acute liver failure","authors":"Keisuke Kakisaka,&nbsp;Tokio Sasaki,&nbsp;Ippeki Nakaya,&nbsp;Takuya Watanabe,&nbsp;Hiroaki Abe,&nbsp;Kenji Yusa,&nbsp;Yudai Fujiwara,&nbsp;Tamami Abe,&nbsp;Akiko Suzuki,&nbsp;Kei Endo,&nbsp;Yuichi Yoshida,&nbsp;Takayoshi Oikawa,&nbsp;Kei Sawara,&nbsp;Akio Miyasaka,&nbsp;Hidekatsu Kuroda,&nbsp;Takayuki Matsumoto","doi":"10.1111/hepr.14083","DOIUrl":"10.1111/hepr.14083","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Acute pancreatitis is a complication of acute liver failure (ALF). This study aimed to investigate the prevalence of and clinical features associated with acute pancreatitis in patients with ALF.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed a cohort of ALF patients without hepatic encephalopathy diagnosed during a period 2011–2018, and compared clinical features between patients with acute pancreatitis and those without. Acute pancreatitis was diagnosed according to the Acute Pancreatitis Clinical Practice Guidelines 2021. A multivariate analysis was carried out to identify factors associated with acute pancreatitis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 83 ALF patients without hepatic encephalopathy (34 men; 11 deaths; 6 liver transplants; median age, 63 years). Acute pancreatitis occurred in nine patients (10.8%). The median time duration from ALF to the onset of acute pancreatitis was 8 days. The survival rate was lower in patients with than those without acute pancreatitis (22% vs. 86%). The model for end-stage liver disease score (hazard ratio 1.10, 95% confidence interval 1.03–1.18) was found to be a significant factor associated with acute pancreatitis, whereas triglyceride, age, and sex were not.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A high model for end-stage liver disease score may be a marker to stratify patients with ALF at a risk of acute pancreatitis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 1","pages":"130-137"},"PeriodicalIF":3.9,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}